An interventional study of iTBS in Hoarding Disorder, Hoarding and Depression, sponsored by University of California, San Diego. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by University of California, San Diego · Not applicable, Interventional, and Treatment
The primary goal of this study is to evaluate whether intermittent theta burst stimulation (iTBS) is effective for treating depression in people who have depression and chronic hoarding disorder (HD). The study will also evaluate whether this treatment can improve HD symptoms, cognitive performance, and brain region connectivity. The study team will investigate how the treatment works for depression, as well as other factors that can enhance or hinder treatment, such as pre-treatment level of depression, cognitive performance, or brain region connectivity.
32 studies on the registry are indexed under Hoarding Disorder; 5 are open to participants now.
This study's enrollment of 14 is below the median of 37 across 28 interventional studies indexed under Hoarding Disorder.
Browse Hoarding Disorder studies →University of California, San Diego is the lead sponsor of 980 studies on the registry; 195 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intermittent Theta Burst Stimulation (a form of transcranial magnetic stimulation) targeting the left dorsolateral prefrontal cortex
Device: iTBS
iTBS targeting the left dorsolateral prefrontal cortex; 20 sessions over 4 weeks.
Also known as: rTMS
Saving Inventory -- Revised
Saving Inventory - Revised, measuring hoarding symptom severity. Min=0, Max=92. Higher scores indicate more severe hoarding symptoms.
Time frame: change from baseline to 8 weeks
Hamilton Rating Scale for Depression
Hamilton Rating Scale for Depression, measuring depression symptom severity. Min=0, Max=50. Higher scores represent more severe depression symptoms.
Time frame: change from baseline to 8 weeks
Hoarding Rating Scale
Hoarding Rating Scale, measuring hoarding symptom severity. Min=0, Max=40. Higher scores represent more severe hoarding symptoms.
Time frame: change from baseline to 8 weeks
Patient Health Questionnaire - 9
Patient Health Questionnaire - 9, measuring depression symptom severity. Min=0, Max=27. Higher scores indicate more severe depression symptoms.
Time frame: change from baseline to 8 weeks
Neuropsychological Global Deficit Score
Neuropsychological Global Deficit Score, measuring global cognitive performance. Min=0, Max=5. Higher scores indicate worse cognitive performance.
Time frame: change from baseline to 8 weeks
Resting State Functional Connectivity
Resting state functional connectivity between subgenual cingulate and dorsolateral prefrontal cortex. There are no mathematical minimums or maximums for this Fisher's Z score. Higher values represent greater connection between brain regions.
Time frame: change from baseline to 4 weeks
Participants were initially recruited from a waitlist for HD treatment in the San Diego, California area. However, participants also found the study online via clinicaltrials.gov
| Milestone | iTBS |
|---|---|
| Started | 11 |
| Completed | 10 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Saving Inventory - Revised, measuring hoarding symptom severity. Min=0, Max=92. Higher scores indicate more severe hoarding symptoms.
| score on a scale | iTBS |
|---|---|
| Saving Inventory -- Revised | 50.6 ± 16.6 |
Hamilton Rating Scale for Depression, measuring depression symptom severity. Min=0, Max=50. Higher scores represent more severe depression symptoms.
| score on a scale | iTBS |
|---|---|
| Hamilton Rating Scale for Depression | 11.0 ± 7.2 |
Hoarding Rating Scale, measuring hoarding symptom severity. Min=0, Max=40. Higher scores represent more severe hoarding symptoms.
| score on a scale | iTBS |
|---|---|
| Hoarding Rating Scale | 11.0 ± 7.2 |
Patient Health Questionnaire - 9, measuring depression symptom severity. Min=0, Max=27. Higher scores indicate more severe depression symptoms.
| score on a scale | iTBS |
|---|---|
| Patient Health Questionnaire - 9 | 10.4 ± 8.5 |
Neuropsychological Global Deficit Score, measuring global cognitive performance. Min=0, Max=5. Higher scores indicate worse cognitive performance.
| Points on a scale | iTBS |
|---|---|
| Neuropsychological Global Deficit Score | .03 ± .06 |
Resting state functional connectivity between subgenual cingulate and dorsolateral prefrontal cortex. There are no mathematical minimums or maximums for this Fisher's Z score. Higher values represent greater connection between brain regions.
| Fisher's Z score | iTBS |
|---|---|
| Resting State Functional Connectivity | -.089 ± .069 |
Collected over from enrollment until end of follow-up, up to 8 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| iTBS | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
3 participants not assigned to treatment due to not completing baseline assessment (1) or not meeting study criteria (2)
| Age, Continuous(years) | iTBS |
|---|---|
| Mean | 52 (27 to 68) |
| Sex: Female, Male(Participants) | iTBS |
|---|---|
| Female | 6 |
| Male | 5 |
| Race (NIH/OMB)(Participants) | iTBS |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | iTBS |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| HAM-D(score on a scale) | iTBS |
|---|---|
| Mean | 22.4 ± 3.2 |
| PHQ-9(score on a scale) | iTBS |
|---|---|
| Mean | 16.6 ± 5.0 |
| HRS(score on a scale) | iTBS |
|---|---|
| Mean | 30.6 ± 5.3 |
| SI-R(score on a scale) | iTBS |
|---|---|
| Mean | 63.7 ± 9.2 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data can be de-identified and made available upon request.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Diego →